This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
APR Applied Pharma Research SA
Drug Names(s): Zolmitriptan Oral Dispersable Film (ODF)
Description: The Zolmitriptan ODF is a very thin polymeric film strip with a size of 3 cm2 and 6 cm2 for the 2.5 mg and 5 mg dosage strengths, respectively. Once placed in the mouth, the ODF dissolves in a few seconds and is swallowed with the saliva without the need of water.
Zolmitriptan is a triptan that binds with high affinity to human recombinant 5-HT1D and 5-HT1B receptors. Zolmitriptan exhibits modest affinity for 5-HT1A receptors, but has no significant affinity (as measured by radioligand binding assays) or pharmacological activity at 5-HT2, 5-HT3, 5-HT4, alpha1-, alpha2- or beta1-adrenergic; H1, H2, histaminic; muscarinic; dopamine1, or dopamine2 receptors. The N-desmethyl metabolite also has high affinity for 5-HT1B/1D and modest affinity for 5-HT1A receptors.
Deal Structure: Zolmitriptan ODF was developed by APR and Labtec in collaboration with Monosol Rx.
Partners: MonoSol Rx Tesa SE
Additional information available to subscribers only: